Market closedNon-fractional
Contineum Therapeutics/CTNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Contineum Therapeutics
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Ticker
CTNM
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
San Diego, United States
Employees
31
Website
www.contineum-tx.com
CTNM Metrics
BasicAdvanced
$517M
Market cap
-
P/E ratio
-$1.42
EPS
-
Beta
-
Dividend rate
Price and volume
Market cap
$517M
Financial strength
Current ratio
19.203
Quick ratio
18.914
Long term debt to equity
0.095
Total debt to equity
0.5
Interest coverage (TTM)
97.09%
Management effectiveness
Valuation
Price to revenue (TTM)
0.937
Price to book
-0.63
Price to tangible book (TTM)
-0.63
Price to free cash flow (TTM)
2.908
Growth
What the Analysts think about CTNM
Analyst Ratings
Majority rating from 3 analysts.
CTNM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.4M
9.09%
Profit margin
0.00%
NaN%
CTNM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$3.55
-
Expected
-$0.46
-$0.35
Surprise
671.74%
-
CTNM News
AllArticlesVideos
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Business Wire·2 weeks ago
Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model
Seeking Alpha·3 weeks ago
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Contineum Therapeutics stock?
Contineum Therapeutics (CTNM) has a market cap of $517M as of July 05, 2024.
What is the P/E ratio for Contineum Therapeutics stock?
The price to earnings (P/E) ratio for Contineum Therapeutics (CTNM) stock is 0 as of July 05, 2024.
Does Contineum Therapeutics stock pay dividends?
No, Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Contineum Therapeutics dividend payment date?
Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Contineum Therapeutics?
Contineum Therapeutics (CTNM) does not currently have a Beta indicator.
Buy or sell Contineum Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.